Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is advancing artificial intelligence and multi-omic biomarker solutions to improve cardiovascular disease detection and management. The company aims to lower barriers to advanced cardiovascular testing by utilizing a simple blood test to provide actionable insights for more informed and timely care decisions.
Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for approximately one in every three deaths. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression.
Cardio Diagnostics is focused on addressing this need by developing advanced solutions that leverage AI and multi-omic biomarkers. By utilizing a simple blood test, the company is lowering barriers to advanced cardiovascular testing, enabling more patients to access early detection and personalized risk assessment.
For more information on the latest news and updates relating to CDIO, visit the company's newsroom at https://ibn.fm/CDIO.
This announcement highlights the potential of AI-driven diagnostics to transform cardiovascular care, offering the possibility of earlier intervention and improved patient outcomes.
